心脏病专家的观点：用于预测心律失常风险的新型心电图生物标志物和计算机模拟模型：我们准备好了吗？
Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?
作者信息
Mason Jay W
机构信息
Division of Cardiology, University of Utah, 50 N. Medical Drive, Salt Lake City, UT 84132, United States.
出版信息
J Electrocardiol. 2017 Nov-Dec;50(6):825-827. doi: 10.1016/j.jelectrocard.2017.08.011. Epub 2017 Aug 15.
The CiPA initiative is well underway, but in its early stages. Are we ready for it? There are several issues that bear on the success of this multidisciplinary effort related to (1) the final testing paradigm that will result, (2) the way in which discrepancies in test methods will be handled, (3) commercialization of the testing methods, (4) quantitative understanding of arrhythmia risk of the 6 non-hERG channels being tested, (5) validity of the CiPA drug list, and (6) ultimate clinical validation.
CiPA计划正在顺利推进，但仍处于早期阶段。我们为此做好准备了吗？有几个问题关系到这项多学科努力的成功，这些问题包括：（1）最终将形成的测试范式；（2）处理测试方法差异的方式；（3）测试方法的商业化；（4）对正在测试 的6种非hERG通道心律失常风险的定量理解；（5）CiPA药物清单的有效性；以及（6）最终的临床验证。
Zotero 插件